These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33669266)

  • 1. Examining the Relationship between Circulating CD4- CD8- Double-Negative T Cells and Outcomes of Immuno-Checkpoint Inhibitor Therapy-Looking for Biomarkers and Therapeutic Targets in Metastatic Melanoma.
    Strippoli S; Fanizzi A; Negri A; Quaresmini D; Nardone A; Armenio A; Sciacovelli AM; Massafra R; De Risi I; De Tullio G; Albano A; Guida M
    Cells; 2021 Feb; 10(2):. PubMed ID: 33669266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.
    Uryvaev A; Passhak M; Hershkovits D; Sabo E; Bar-Sela G
    Med Oncol; 2018 Jan; 35(3):25. PubMed ID: 29388007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
    Yan Y; Wang X; Liu C; Jia J
    BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
    Inomata M; Kado T; Okazawa S; Imanishi S; Taka C; Kambara K; Hirai T; Tanaka H; Tokui K; Hayashi K; Miwa T; Hayashi R; Matsui S; Tobe K
    Anticancer Res; 2019 Dec; 39(12):6887-6893. PubMed ID: 31810958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The proportion of circulating CD45RO
    Tietze JK; Angelova D; Heppt MV; Reinholz M; Murphy WJ; Spannagl M; Ruzicka T; Berking C
    Eur J Cancer; 2017 Apr; 75():268-279. PubMed ID: 28242504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer.
    Manjarrez-Orduño N; Menard LC; Kansal S; Fischer P; Kakrecha B; Jiang C; Cunningham M; Greenawalt D; Patel V; Yang M; Golhar R; Carman JA; Lezhnin S; Dai H; Kayne PS; Suchard SJ; Bernstein SH; Nadler SG
    Front Immunol; 2018; 9():1613. PubMed ID: 30123214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients.
    Pirozyan MR; McGuire HM; Emran AA; Tseng HY; Tiffen JC; Lee JH; Carlino MS; Menzies AM; Long GV; Scolyer RA; Fazekas de St Groth B; Hersey P
    Front Immunol; 2020; 11():372. PubMed ID: 32210968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
    Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
    Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease.
    Diem S; Hasan Ali O; Ackermann CJ; Bomze D; Koelzer VH; Jochum W; Speiser DE; Mertz KD; Flatz L
    Cancer Immunol Immunother; 2018 Jan; 67(1):39-45. PubMed ID: 28894934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.
    Mazzaschi G; Facchinetti F; Missale G; Canetti D; Madeddu D; Zecca A; Veneziani M; Gelsomino F; Goldoni M; Buti S; Bordi P; Aversa F; Ardizzoni A; Quaini F; Tiseo M
    Lung Cancer; 2019 Jan; 127():153-163. PubMed ID: 30642544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.
    Reschke R; Gussek P; Boldt A; Sack U; Köhl U; Lordick F; Gora T; Kreuz M; Reiche K; Simon JC; Ziemer M; Kunz M
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
    Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.
    Flynn MJ; Larkin JMG
    Expert Opin Pharmacother; 2017 Oct; 18(14):1477-1490. PubMed ID: 28820000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.
    de Coaña YP; Wolodarski M; Poschke I; Yoshimoto Y; Yang Y; Nyström M; Edbäck U; Brage SE; Lundqvist A; Masucci GV; Hansson J; Kiessling R
    Oncotarget; 2017 Mar; 8(13):21539-21553. PubMed ID: 28423487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.
    Wyluda EJ; Cheng J; Schell TD; Haley JS; Mallon C; Neves RI; Robertson G; Sivik J; Mackley H; Talamo G; Drabick JJ
    Cancer Biol Ther; 2015; 16(5):662-70. PubMed ID: 25806780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.